TL;DR: Curaleaf Holdings (CURLF), the largest U.S. cannabis multi-state operator by revenue, posted a 321.72% one-year return through mid-June 2026 as institutional interest in large-cap cannabis names accelerated on rescheduling positioning. With Q1 FY26 revenue of $324.23M and earnings scheduled for August 5, Curaleaf enters Q3 2026 as the highest-revenue MSO in the sector — though its path to GAAP profitability remains the central thesis question for investors.
Market Analysis
Curaleaf Holdings opened Q3 2026 carrying one of the most striking twelve-month return profiles in the cannabis equity complex. The +321.72% one-year gain through mid-June reflects a market that substantially re-rated CURLF’s enterprise value from depressed lows, driven by a combination of rescheduling optimism, revenue scale, and repositioning of the company’s international operations.
The stock trades on the OTC Pink market with a bid/ask spread near $3.63–$3.65, against a 52-week range of $2.16 to $15.15. The current price sits materially below the 52-week high, indicating that the sector-wide re-rating that drove the one-year return has partially given back gains — creating a reset in expectations heading into the August earnings print.
Market capitalization stands at $2.76 billion on a revenue base of approximately $1.29 billion (TTM), implying a price-to-sales multiple of roughly 2.16x. The enterprise value of $3.49 billion yields an EV/Revenue ratio of 2.71x and an EV/EBITDA of 15.40x — multiples that price in continued operational scale and eventual margin normalization, but leave limited room for execution misses.
Q1 FY26 revenue of $324.23M established a strong baseline as the company entered its fiscal second quarter. With YTD return of +35.28% and average daily volume near 454,909 shares, Curaleaf maintains among the highest OTC liquidity profiles in the cannabis space — a characteristic that continues to attract institutional trading interest even as the stock trades below its 2025 highs.
The diluted EPS (TTM) of -$0.42 is the persistent challenge in the Curaleaf thesis. Unlike Green Thumb, which generates positive GAAP earnings, Curaleaf has not yet delivered consistent bottom-line profitability. The 280E federal tax liability remains a significant drag: until rescheduling produces relief, Curaleaf’s effective tax rate on cannabis income continues to compress realized earnings well below operating cash flow.
Regulatory and Market Context
Curaleaf’s Q3 2026 positioning is directly linked to the federal rescheduling narrative in a way few other operators match. As the highest-revenue MSO in the sector, Curaleaf carries proportionally greater 280E exposure — and therefore stands to benefit most in absolute dollar terms from rescheduling-driven tax normalization. Analyst consensus price target of $15.00 (average) implies that the market assigns material probability to this catalyst resolving within the investment horizon.
The company’s Q3 trajectory will also be shaped by its international segment, which includes operations in Germany, Australia, and other medical cannabis markets. As European medical cannabis regulations mature — particularly Germany’s partial liberalization framework — Curaleaf’s international revenue line provides a diversification component that purely U.S.-focused operators cannot offer.
Domestically, Curaleaf operates across 17 states with over 150 dispensaries, giving it one of the broadest geographic footprints in the MSO universe. This scale creates operational complexity but also provides revenue resilience when individual state markets underperform. The August 5 earnings date will be scrutinized closely for management commentary on state-level performance, cost structure progress, and any updated rescheduling timeline assumptions.
The YTD return of +35.28% through mid-June outpaces the S&P/TSX benchmark of +9.77%, but the stock’s OTC market structure continues to limit the institutional capital formation that would be available under exchange listing. Any regulatory development that improves the path to Nasdaq or NYSE uplisting remains a secondary catalyst for CURLF.
Conclusion
Curaleaf enters Q3 2026 as the revenue leader of the U.S. cannabis MSO complex — a position that makes it both the clearest rescheduling beneficiary and the most scrutinized name in the sector heading into August earnings. The gap between the 321% one-year return and the current $3.65 trading level versus the $15.00 analyst target captures the high-variance nature of the Curaleaf thesis: the fundamental case is compelling at scale, but execution and federal policy remain the decisive variables.
Investors positioning in CURLF ahead of the August 5 earnings release should focus on management’s 280E accrual methodology, international revenue contribution, and any guidance on state market maturation timelines. Until the DEA rescheduling process concludes, CURLF will continue to trade as a policy-beta name as much as a fundamental one.
Follow daily price action for Curaleaf and the full cannabis equity complex via the cannabis stock tracker.